Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q4 2020 · 10-K
Revenue$0.00$0.00no prior Q4 2019 on file Net Income-$3.27M-$3.27MN/M vs Q4 2019 EPS Diluted-$0.08-$0.08N/M vs Q4 2019 Operating Income-$3,263,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
derived
ended Mar 31, 2020 · filed Jun 29, 2020 · 90 d after period end